PURPOSE: To examine immune processes in the lacrimal gland of @entity1 with @entity2132 ( @entity2132 ) by evaluating the expression of surface molecules associated with T-cell activation. METHODS: Antibodies to @entity404 , @entity405 , @entity2280 , @entity2936 , @entity2071 , @entity7938 , @entity2937 , @entity11603 , and HLA-DR were used for immunohistochemical analysis of lacrimal gland biopsy specimens obtained from nine @entity1 with @entity2132 and five with Sj  @entity244 ( @entity244 ). The regions of interest were further assessed by transmission electron microscopy. RESULTS: @entity404 (+) and @entity405 (+) T cells were mainly detected in the periductal areas of the glands of @entity1 with @entity2132 , but were distributed throughout the acinar areas in @entity1 with @entity244 . In the periductal areas of @entity1 with @entity2132 , a subpopulation of @entity404 (+) and @entity405 (+) T cells expressed the activation marker @entity11603 . In addition, @entity404 (+) and @entity405 (+) T cells were colocalized with mononuclear infiltrates and stromal fibroblasts expressing the full component of surface molecules necessary for antigen presentation, including HLA-DR, @entity2071 , @entity2936 , @entity7938 , and @entity2937 . Electron microscopy revealed activated fibroblasts that embraced lymphocytes and macrophages with their processes. Also, there were more @entity405 (+) T cells in the glandular epithelia of @entity1 with @entity2132 than in those with @entity244 . Intraepithelial T cells were attached to epithelial cells by several primitive contacts and colocalized with dead cells. CONCLUSIONS: The results strongly suggest that @entity404 (+) and @entity405 (+) T cells in the lacrimal glands of @entity1 with @entity2132 are primarily activated in the periductal area through antigenic stimulation by potent antigen-presenting cells and stromal fibroblasts, and exert various effector functions, including cytotoxic effects on glandular epithelial cells.

Periductal area as the primary site for T-cell activation in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity2937 :: ('942', 'Gene') :: ['CD86'] @entity7938 :: ('941', 'Gene') :: ['CD80'] @entity2936 :: ('958', 'Gene') :: ['CD40'] @entity11603 :: ('959', 'Gene') :: ['CD154'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['cGVHD', 'chronic graft-versus-host disease'] @entity244 :: ('MESH:D014899', 'Disease') :: ["gren's syndrome", 'SS'] @entity2071 :: ('3383', 'Gene') :: ['CD54'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity405 :: ('925', 'Gene') :: ['CD8']
@entity2132 :: (MESH:D006086,Disease) :: ['lacrimal gland chronic graft-versus-host disease']
